Welcome!

News Feed Item

Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced the membership of its Scientific Advisory Board, comprised of internationally recognized food allergy experts.

The Scientific Advisory Board members and their academic affiliations are:

  • Dr. Kirsten Beyer, University Hospital Charité, Berlin, Germany
  • Dr. A. Wesley Burks, University of North Carolina, Chapel Hill
  • Dr. Thomas Casale, University of South Florida, Tampa
  • Dr. Jonathan Hourihane, University College Cork, Ireland
  • Dr. Stacie Jones, University of Arkansas for Medical Sciences, Little Rock

“As we carry out our Phase 3 PALISADE trial and prepare to start the RAMSES and ARTEMIS trials for AR101 for the treatment of peanut allergy, we are seeking critical peer review of our upcoming development-stage programs from these expert research physicians,” said Daniel Adelman, M.D., Chief Medical Officer of Aimmune. “Their experienced, evidence-based critique will help us in the planning and optimization of forthcoming clinical trials, development strategy and selection of our future therapeutic targets.”

All of the members of Aimmune’s Scientific Advisory Board are investigators in PALISADE, Aimmune’s current Phase 3 clinical trial of AR101 for the treatment of peanut allergy. AR101 is Aimmune’s biologic oral immunotherapy for desensitization of patients with peanut allergy.

“Throughout our clinical trials, we have had the good fortune to work with many dedicated and insightful allergists, and we look forward to continuing to benefit from their knowledge and experience. We are delighted to establish a formal review structure with this group of exceptional researchers, who together have contributed so much to advancing the field of food allergy,” said Aimmune CEO Stephen Dilly, M.B.B.S., Ph.D. “Our PALISADE trial gave us the opportunity to expand our clinical activity in both the United States and Europe and work directly with Dr. Casale, Dr. Beyer and Dr. Hourihane, each of whom has informed our perspective on critical issues. Dr. Burks and Dr. Jones, of course, have been invaluable guides during not only our current and earlier clinical trials, but also during the foundation of our company itself, as they generously provided data that formed the foundation of our AR101 program. We are truly grateful to have the support of all of these physicians as we pursue our global development programs aimed at improving the lives of people with food allergies.”

Kirsten Beyer, M.D., is a Professor in the Department of Pediatric Pneumology and Immunology at University Hospital Charité in Berlin. Her research experience spans the spectrum of pediatric allergy, with a focus on food allergy. Her interests include food allergy prevention, diagnosis and treatment. Currently, her group is studying the induction of oral tolerance through oral immunotherapy in food-allergic children and the primary prevention of hen’s egg allergy through early hen’s egg feeding, among other studies. She is also part of the EU-funded food allergy project EuroPrevall, studying a European birth cohort of more than 12,000 babies, which will be re-evaluated at school age within the EU-funded project iFAAM. Dr. Beyer qualified as an M.D. at the Free University in Berlin, Germany, and carried out her pediatric training and fellowship at the Humboldt University in Berlin. She was also a visiting scientist at Johns Hopkins University and an Assistant Professor of Pediatrics at Mount Sinai School of Medicine.

A. Wesley Burks, M.D., is Executive Dean for the University of North Carolina School of Medicine as well as the Curnen Distinguished Professor in the Department of Pediatrics. Dr. Burks heads a research team whose work centers on the molecular identification of the allergens in specific foods, a better understanding of the mechanism of adverse food reactions, and the development of treatment for food allergy in pre-clinical and clinical studies. He and his colleagues have several ongoing clinical studies with different types of mucosal immunotherapy. Dr. Burks is also a principal investigator for the Consortium of Food Allergy Research (CoFAR), which was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies. Dr. Burks earned his medical degree at the University of Arkansas for Medical Sciences, then completed a pediatric residency at the Arkansas Children's Hospital and a fellowship in allergy and immunology at Duke University Medical Center. Dr. Burks is a past Chair and member of the NIH Hypersensitivity, Autoimmune, and Immune-mediated Diseases study section and is Past President of the American Academy of Allergy, Asthma and Immunology, where he served from 2012 to 2013.

Thomas B. Casale, M.D., is a Professor of Medicine and Pediatrics at the College of Medicine at the University of South Florida in Tampa, Florida. Dr. Casale's clinical and basic research interests are directed toward determination and treatment of the pathophysiologic mechanisms involved in asthma and allergic diseases. He is currently the director of clinical and translational research and is actively involved in examining immunomodulators for the treatment of inflammatory disorders. He is also very active in the development of educational programs in allergy and immunology for local, national and international meetings. Dr. Casale earned his medical degree from the Rosalind Franklin University of Medicine and Science, Chicago Medical School, then completed his residency at Baylor College of Medicine and an allergy/immunology fellowship at the National Institutes of Health. He served as President of the American Academy of Allergy, Asthma and Immunology from 2007 to 2008.

Jonathan Hourihane, M.D., is a Professor of Paediatrics and Child Health at University College Cork in Ireland. His research interests focus on the exploration of the link between skin barrier dysfunction and systemic allergic disorders, threshold doses of food allergens, immunomodulation of established allergic responses, prevention of allergic sensitization, and evaluation of quality of life in food allergic children. He is co-principal investigator for the BASELINE birth cohort study, which is tracking more than 2,000 Irish children from soon after conception over several years to study the effects of intrauterine growth restriction, the incidence and prevalence of food allergy and eczema in early childhood, and the incidence and effects of maternal and infant vitamin D status on growth and health. He was Founding Secretary of the Irish Association of Allergy and Immunology and is Founding Chairman of the Irish Food Allergy Network. Dr. Hourihane earned his Bachelor of Medicine (M.B.), Bachelor of Surgery (B.Ch.), and Bachelor of Obstetrics (B.A.O.) degrees at Dublin University, Trinity College and an M.D. from the University of Southampton.

Stacie M. Jones, M.D., is a Professor of Pediatrics and Chief of Allergy and Immunology at the University of Arkansas for Medical Sciences and Arkansas Children's Hospital. She is also a researcher at the Arkansas Children's Research Institute. Her research focuses on both clinical and translational investigation of food allergy and eosinophilic gastrointestinal disorders, as well as on asthma and lung disease. Dr. Jones is also a principal investigator for the Consortium of Food Allergy Research (CoFAR), which was established in July 2005 by the National Institute of Allergy and Infectious Diseases (NIAID) to conduct both observational and clinical studies to answer questions related to food allergies. Dr. Jones earned her medical degree at the University of Arkansas for Medical Sciences and completed her pediatrics residency there and at Arkansas Children's Hospital, followed by a fellowship in Pediatric Allergy and Immunology at Johns Hopkins Hospital.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts. For more information, please see www.aimmune.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations for the its Scientific Advisory Board; Aimmune’s expectations for its Phase 3 trials of AR101, including PALISADE, RAMSES and ARTEMIS; Aimmune’s expectations regarding the potential benefits of AR101; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the expectation that Aimmune will need additional funds to finance its operations; the company’s ability to initiate and/or complete clinical trials; the unpredictability of the regulatory process; the possibility that Aimmune’s clinical trials will not be successful; Aimmune’s dependence on the success of AR101; the company’s reliance on third parties for the manufacture of the company’s product candidates; possible regulatory developments in the United States and foreign countries; and the company’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, provideed economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session also included a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
"Dice has been around for the last 20 years. We have been helping tech professionals find new jobs and career opportunities," explained Manish Dixit, VP of Product and Engineering at Dice, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Infrastructure is widely available, but who’s managing inbound/outbound traffic? Data is created, stored, and managed online – who is protecting it and how? In his session at 19th Cloud Expo, Jaeson Yoo, SVP of Business Development at Penta Security Systems Inc., discussed how to keep any and all infrastructure clean, safe, and efficient by monitoring and filtering all malicious HTTP/HTTPS traffic at the OSI Layer 7. Stop attacks and web intruders before they can enter your network.
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, will discuss how AI can simplify cloud operations. He will cover the following topics: why clou...
The many IoT deployments around the world are busy integrating smart devices and sensors into their enterprise IT infrastructures. Yet all of this technology – and there are an amazing number of choices – is of no use without the software to gather, communicate, and analyze the new data flows. Without software, there is no IT. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, Dave McCarthy, Director of Products at Bsquare Corporation; Alan Williamson, Principal...
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, discussed how VPaaS enables you to move fast, creating scalable video experiences that reach your aud...
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, attendees learned about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how ...
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lead...
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
"At ROHA we develop an app called Catcha. It was developed after we spent a year meeting with, talking to, interacting with senior citizens watching them use their smartphones and talking to them about how they use their smartphones so we could get to know their smartphone behavior," explained Dave Woods, Chief Innovation Officer at ROHA, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.